Your browser doesn't support javascript.
loading
Engineered Salmonella enterica serovar Typhimurium overcomes limitations of anti-bacterial immunity in bacteria-mediated tumor therapy.
Felgner, Sebastian; Kocijancic, Dino; Frahm, Michael; Heise, Ulrike; Rohde, Manfred; Zimmermann, Kurt; Falk, Christine; Erhardt, Marc; Weiss, Siegfried.
Affiliation
  • Felgner S; Department of Molecular Immunology, Helmholtz Centre for Infection Research, Braunschweig, Lower Saxony, Germany.
  • Kocijancic D; Infection Biology of Salmonella, Helmholtz Centre for Infection Research, Braunschweig, Lower Saxony, Germany.
  • Frahm M; Department of Molecular Immunology, Helmholtz Centre for Infection Research, Braunschweig, Lower Saxony, Germany.
  • Heise U; Department of Molecular Immunology, Helmholtz Centre for Infection Research, Braunschweig, Lower Saxony, Germany.
  • Rohde M; Mouse-Pathology Service Unit, Helmholtz Centre for Infection Research, Braunschweig, Lower Saxony, Germany.
  • Zimmermann K; Central Facility for Microscopy, Helmholtz Centre for Infection Research, Braunschweig, Lower Saxony, Germany.
  • Falk C; Symbio Gruppe GmbH & Co KG, Herborn, Lower Saxony, Germany.
  • Erhardt M; Institute of Transplant Immunology, Medical School Hannover, Hannover, Hessia, Germany.
  • Weiss S; Infection Biology of Salmonella, Helmholtz Centre for Infection Research, Braunschweig, Lower Saxony, Germany.
Oncoimmunology ; 7(2): e1382791, 2018.
Article in En | MEDLINE | ID: mdl-29308303
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncoimmunology Year: 2018 Type: Article Affiliation country: Germany
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncoimmunology Year: 2018 Type: Article Affiliation country: Germany